ADAP
Price
$0.24
Change
+$0.01 (+4.17%)
Updated
Jun 27 closing price
Capitalization
63.8M
38 days until earnings call
ATXS
Price
$5.44
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
316.03M
43 days until earnings call
Interact to see
Advertisement

ADAP vs ATXS

Header iconADAP vs ATXS Comparison
Open Charts ADAP vs ATXSBanner chart's image
Adaptimmune Therapeutics
Price$0.24
Change+$0.01 (+4.17%)
Volume$937.87K
Capitalization63.8M
Astria Therapeutics
Price$5.44
Change-$0.00 (-0.00%)
Volume$50
Capitalization316.03M
ADAP vs ATXS Comparison Chart in %
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. ATXS commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Buy and ATXS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ADAP: $0.25 vs. ATXS: $5.44)
Brand notoriety: ADAP and ATXS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 87% vs. ATXS: 0%
Market capitalization -- ADAP: $63.8M vs. ATXS: $316.03M
ADAP [@Biotechnology] is valued at $63.8M. ATXS’s [@Biotechnology] market capitalization is $316.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileATXS’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • ATXS’s FA Score: 0 green, 5 red.
According to our system of comparison, both ADAP and ATXS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 4 TA indicator(s) are bullish while ATXS’s TA Score has 6 bullish TA indicator(s).

  • ADAP’s TA Score: 4 bullish, 6 bearish.
  • ATXS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ATXS is a better buy in the short-term than ADAP.

Price Growth

ADAP (@Biotechnology) experienced а -3.16% price change this week, while ATXS (@Biotechnology) price change was -7.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ADAP is expected to report earnings on Aug 06, 2025.

ATXS is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($316M) has a higher market cap than ADAP($63.8M). ATXS YTD gains are higher at: -39.150 vs. ADAP (-54.520). ADAP has higher annual earnings (EBITDA): -50.18M vs. ATXS (-124.4M). ATXS has more cash in the bank: 295M vs. ADAP (59.6M). ATXS has less debt than ADAP: ATXS (5.06M) vs ADAP (48.7M). ADAP has higher revenues than ATXS: ADAP (180M) vs ATXS (0).
ADAPATXSADAP / ATXS
Capitalization63.8M316M20%
EBITDA-50.18M-124.4M40%
Gain YTD-54.520-39.150139%
P/E RatioN/AN/A-
Revenue180M0-
Total Cash59.6M295M20%
Total Debt48.7M5.06M962%
FUNDAMENTALS RATINGS
ADAP vs ATXS: Fundamental Ratings
ADAP
ATXS
OUTLOOK RATING
1..100
5379
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6558
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (53) in the Biotechnology industry is in the same range as ATXS (59). This means that ADAP’s stock grew similarly to ATXS’s over the last 12 months.

ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ATXS (100). This means that ADAP’s stock grew similarly to ATXS’s over the last 12 months.

ADAP's SMR Rating (97) in the Biotechnology industry is in the same range as ATXS (97). This means that ADAP’s stock grew similarly to ATXS’s over the last 12 months.

ATXS's Price Growth Rating (58) in the Biotechnology industry is in the same range as ADAP (65). This means that ATXS’s stock grew similarly to ADAP’s over the last 12 months.

ATXS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ADAP (100). This means that ATXS’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPATXS
RSI
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 13 days ago
77%
Bullish Trend 14 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BQCNF110.00N/A
N/A
Banque Cantonale Vaudoise
CCTC0.51N/A
N/A
Catalyst Crew Technologies Corp.
MRSKF21.43N/A
N/A
DMG Mori Co Ltd
NACB75.00N/A
N/A
NATIONAL CAP BANCORP INC.
YUMSF1.37N/A
N/A
Demae Can Co Ltd.

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with AKBA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
+1.16%
AKBA - ADAP
41%
Loosely correlated
N/A
AUTL - ADAP
33%
Poorly correlated
N/A
ATXS - ADAP
33%
Poorly correlated
N/A
CSLLY - ADAP
32%
Poorly correlated
-2.96%
ELVN - ADAP
30%
Poorly correlated
-3.95%
More

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with DNLI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
N/A
DNLI - ATXS
57%
Loosely correlated
-2.69%
CRNX - ATXS
54%
Loosely correlated
-0.10%
XENE - ATXS
54%
Loosely correlated
+0.62%
TRDA - ATXS
53%
Loosely correlated
-1.57%
APGE - ATXS
52%
Loosely correlated
N/A
More